Chagas disease in the United States: a public health approach

C Bern, LA Messenger, JD Whitman… - Clinical microbiology …, 2019 - Am Soc Microbiol
Trypanosoma cruzi is the etiological agent of Chagas disease, usually transmitted by
triatomine vectors. An estimated 20 to 30% of infected individuals develop potentially lethal …

[HTML][HTML] WHF IASC roadmap on Chagas disease

LE Echeverría, R Marcus, G Novick, S Sosa-Estani… - Global …, 2020 - ncbi.nlm.nih.gov
Background: Chagas Disease is a neglected tropical disease caused by the protozoan
Trypanosoma cruzi, with some of the most serious manifestations affecting the …

[HTML][HTML] New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind …

F Torrico, J Gascón, F Barreira, B Blum… - The Lancet Infectious …, 2021 - thelancet.com
Summary Background Current treatment for Chagas disease with the only available drugs,
benznidazole or nifurtimox, has substantial limitations, including long treatment duration and …

Chagas disease

AS de Sousa, D Vermeij, AN Ramos, AO Luquetti - The Lancet, 2024 - thelancet.com
Chagas disease persists as a global public health problem due to the high morbidity and
mortality burden. Despite the possibility of a cure and advances in transmission control …

Chagas disease

NS Hochberg, SP Montgomery - Annals of internal medicine, 2023 - acpjournals.org
Chagas disease, which is caused by infection with the parasite Trypanosoma cruzi, is a
leading neglected tropical disease in the United States. An estimated 240 000 to 350 000 …

The current drug discovery landscape for trypanosomiasis and leishmaniasis: Challenges and strategies to identify drug targets

F Altamura, R Rajesh, CMC Catta‐Preta… - Drug development …, 2022 - Wiley Online Library
Human trypanosomiasis and leishmaniasis are vector‐borne neglected tropical diseases
caused by infection with the protozoan parasites Trypanosoma spp. and Leishmania spp …

Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas' disease

Y Jackson, B Wyssa, F Chappuis - Journal of Antimicrobial …, 2020 - academic.oup.com
Abstract Background Current options for Chagas' disease treatment are restricted to
benznidazole and nifurtimox. To the best of our knowledge, no study has ever compared …

[HTML][HTML] SBC guideline on the diagnosis and treatment of patients with cardiomyopathy of chagas disease–2023

JA Marin-Neto, A Rassi Jr, GMM Oliveira… - Arquivos Brasileiros …, 2023 - SciELO Brasil
SciELO - Brazil - Diretriz da SBC sobre Diagnóstico e Tratamento de Pacientes com
Cardiomiopatia da Doença de Chagas – 2023 Diretriz da SBC sobre Diagnóstico e Tratamento …

New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 …

C Alonso-Vega, JA Urbina, S Sanz, MJ Pinazo… - BMJ open, 2021 - bmjopen.bmj.com
Introduction Chagas disease (CD) affects~ 7 million people worldwide. Benznidazole (BZN)
and nifurtimox (NFX) are the only approved drugs for CD chemotherapy. Although both …

Efficacy and safety of nifurtimox in pediatric patients with Chagas disease: results at 4-year follow-up in a prospective, historically controlled study (CHICO SECURE)

J Altcheh, V Sierra, T Ramirez… - Antimicrobial Agents …, 2023 - Am Soc Microbiol
Nifurtimox is recommended for the treatment of Chagas disease; however, long-term follow-
up data are scarce. This prolonged follow-up phase of the prospective, historically …